<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628719</url>
  </required_header>
  <id_info>
    <org_study_id>AA KAMRC</org_study_id>
    <nct_id>NCT00628719</nct_id>
  </id_info>
  <brief_title>Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis</brief_title>
  <official_title>A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banaras Hindu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banaras Hindu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the efficacy of single dose amphotericin B in the
      treatment of Visceral Leishmaniasis (VL) in India.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to evaluate the efficacy of single dose amphotericin B in the
      treatment of VL in India.

      Primary objective: Comparison of the efficacy of single dose of 10 mg/kg of liposomal
      amphotericin B to amphotericin B deoxycholate with regards to final cure rates

      Secondary objective:. Comparison of the safety of single dose of 10 mg/kg of liposomal
      amphotericin B to amphotericin B deoxycholate when administered in the proposed dosage
      regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final cure rate at six months after the end of treatment</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial cure after the end of treatment</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single dose of 10 mg/kg of liposomal amphotericin B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Amphotericin B</intervention_name>
    <description>a single dose of 10 mg/kg of liposomal amphotericin B</description>
    <arm_group_label>1</arm_group_label>
    <other_name>AmBisome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amphotericin B deoxycholate</intervention_name>
    <description>amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children and adults 2-65 years of age (inclusive) of either gender.

          -  Diagnosis of VL confirmed by spleen or bone marrow aspirate.

          -  Clinical signs and symptoms compatible with VL.

          -  Biochemical and haematological test values as follows:

          -  Haemoglobin &gt; 3.5g/100mL

          -  White blood cell count &gt; 0.75 x109/L

          -  Platelet count &gt; 40 x 109/L

          -  AST, ALT and alkaline phosphatase &lt; 5 times upper normal limit

          -  Prothrombin time &lt; 4 seconds above control

          -  Serum creatinine levels - 1.5 times upper normal limit

          -  Serum potassium levels within normal limits

          -  HIV negative.

        Exclusion Criteria:

          -  A history of intercurrent or concurrent diseases (e.g. chronic alcohol consumption or
             drug addiction; renal, hepatic, cardiovascular or CNS disease; diabetes; tuberculosis;
             other infectious or major psychiatric diseases) that may introduce variables that
             affect the outcome of the study.

          -  Any condition which the investigator thinks may prevent the patient from completing
             the study therapy and subsequent follow-up.

          -  Proteinuria (&gt; 2+).

          -  A history of allergy or hypersensitivity to amphotericin B

          -  Previous treatment for VL within two weeks of enrollment into the study.

          -  Prior treatment failures with amphotericin B.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Sundar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Banaras Hindu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kala-azar Medical Research Center, Rambag Road</name>
      <address>
        <city>Muzaffarpur</city>
        <zip>842001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Shyam Sundar</name_title>
    <organization>Banaras Hindu University</organization>
  </responsible_party>
  <keyword>Visceral leishmaniasis</keyword>
  <keyword>India</keyword>
  <keyword>Liposomal Amphotericin B</keyword>
  <keyword>Amphotericin B deoxycholate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Amphotericin B, deoxycholate drug combination</mesh_term>
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

